X-Rx Discovery

X-Rx Discovery is a Boulder-based biotechnology company specializing in the design and development of next-generation small molecule inhibitors. The company's core expertise lies in targeting kinases and other enzymes critical to the progression of cancer and inflammatory conditions. Founded in 2012 by former Array BioPharma scientists, X-Rx was acquired by Dainippon Sumitomo Pharma (now Sumitomo Pharma) in 2014 to enhance its early-stage drug discovery engine. Today, it operates as an integral research unit within the Sumitomo Pharma America ecosystem, focusing on high-selectivity molecules for complex diseases. The company's platform combines structure-based drug design with deep biological insights to produce clinical-stage candidates.